{"created":"2023-07-27T06:59:23.572112+00:00","id":58957,"links":{},"metadata":{"_buckets":{"deposit":"0d0c974a-3a57-410e-894d-7e1d93845968"},"_deposit":{"created_by":18,"id":"58957","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"58957"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00058957","sets":["4200:1874:1875"]},"author_link":["103662","78846","22513","78849","87","102","85011","73627","103663","115","73626","26130","43"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"659","bibliographicPageStart":"651","bibliographicVolumeNumber":"66","bibliographic_titles":[{"bibliographic_title":"Chemical and Pharmaceutical Bulletin"}]}]},"item_4_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小川, 数馬"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"柴, 和弘"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"絹谷, 清剛"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"小谷, 明"}],"nameIdentifiers":[{},{},{},{}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Radiolabeled cyclic peptides containing the (Arg-Gly-Asp) RGD sequence for use in positron emission tomography (PET) imaging, single-photon emission computed tomography (SPECT) imaging, and targeted radionuclide therapy of cancer have been reported. In this study, RGD was used as a model carrier peptide for diagnosis and therapy of cancer. To evaluate the characteristics of radiohalogen-labeled peptides, several kinds of labeled RGD peptides [125I-c(RGDyK), 77Br-c(RGDyK), [125I]SIB-c(RGDfK), [77Br]SBrB-c(RGDfK), [125I]SIB-EG2-c(RGDfK), and [77Br]SBrB-EG2-c(RGDfK)] were designed, prepared, and evaluated. In these initial studies, 77Br (t1/2=57.0h) and 125I (t1/2=59.4d) were used because of their longer half-lives. Precursor peptides were synthesized using a standard 9-fluorenylmethyloxycarbonyl (Fmoc)-based solid-phase methodology. Radiolabeled peptides were prepared by chloramine-T method or conjugation of RGD peptides with [125I]N-succinimidyl 3-iodobenzoate ([125I]SIB) or [77Br]N-succinimidyl 3-bromobenzoate ([77Br]SBrB). Measurement of the partition coefficients, integrin binding assay, and biodistribution experiments in tumor-bearing mice were performed. 125I and 77Br labeling were successfully performed using similar methods, and in vitro characteristics and biodistributions were similar between the 125I-labeled and corresponding 77Br-labeled peptides. [125I]SIB- and [77Br]SBrB-conjugated RGD peptides showed higher partition coefficients, lower tumor uptakes, and higher intestinal uptake than 125I-c(RGDyK) and 77Br-c(RGDyK). [125I]SIB-EG2-c(RGDfK) and [77Br]SBrB-EG2-c(RGDfK), which possess an ethylene glycol linker, decreased lipophilicity and uptake in intestine compared with [125I]SIB-c(RGDfK) and [77Br]SBrB-c(RGDfK), which possess no linker. However, the improvement in biodistribution of [125I]SIB-EG2-c(RGDfK) and [77Br]SBrB-EG2-c(RGDfK)] was insufficient. In conclusion, directly radiohalogenated c(RGDyK) peptides are potentially more useful for tumor imaging and therapy than indirectly radiohalogenated ones. © 2018 The Pharmaceutical Society of Japan.","subitem_description_type":"Abstract"}]},"item_4_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学疾患モデル総合研究センター","subitem_description_type":"Other"}]},"item_4_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00065219","subitem_identifier_reg_type":"JaLC"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Pharmaceutical Society of Japan"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1248/cpb.c18-00081","subitem_relation_type_select":"DOI"}}]},"item_4_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://www.jstage.jst.go.jp/browse/cpb/-char/ja/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.jstage.jst.go.jp/browse/cpb/-char/ja/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://www.pharm.or.jp/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.pharm.or.jp/","subitem_relation_type_select":"URI"}}]},"item_4_rights_23":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © Pharmaceutical Society of Japan 日本薬学会"}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA00602100","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0009-2363","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":" 1347-5223","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ogawa, Kazuma"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Takeda, Takuya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yokokawa, Masaru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yu, Jing"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Makino, Akira"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kiyono, Yasushi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shiba, Kazuhiro"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Kinuya, Seigo"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Odani, Akira"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-01-28"}],"displaytype":"detail","filename":"ME-PR-SHIBA-K-66-651.pdf","filesize":[{"value":"569.7 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-SHIBA-K-66-651.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/58957/files/ME-PR-SHIBA-K-66-651.pdf"},"version_id":"b0020541-7e71-4189-801a-10d6ab61960b"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Comparison of radioiodine- or radiobromine-labeled rgd peptides between direct and indirect labeling methods","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Comparison of radioiodine- or radiobromine-labeled rgd peptides between direct and indirect labeling methods"}]},"item_type_id":"4","owner":"18","path":["1875"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-01-28"},"publish_date":"2022-01-28","publish_status":"0","recid":"58957","relation_version_is_last":true,"title":["Comparison of radioiodine- or radiobromine-labeled rgd peptides between direct and indirect labeling methods"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T10:17:42.432826+00:00"}